131 results
8-K
u9ncsy1o2eqf
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
w251h24iwevy 6604
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
1l52 4ko8k
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
zhb79afqmuw6r uo
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
ujv9t4n03qncwm
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
aukk69zq1 dcobo
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
qcskw6qhq2o38m8uay
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
jepss59n99f wr8
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
qgj57hg5b4vu wc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
dygw3cvgu9bb
30 May 23
Business combination disclosure
4:21pm
8-K
wpd9u
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
ucc5bw vrqkgn5w
22 May 23
Business combination disclosure
7:01am
8-K
w44wxge4xdb
22 May 23
Other Events
6:59am